Pancreatic Cancer Research

ResearcherKurume UniversityActive in the last 2 years

Keisuke Miwa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2456-0358; OpenAlex author ID A5018753888. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 3 papers · 2025: 6 papers · 2026: 1 paper

Papers 13

  1. Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 St… Co-author DOI 10.1111/ajco.70041↗
  2. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NA… Co-author DOI 10.1016/j.esmogo.2025.100150↗
  3. Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 Studie… Co-author DOI 10.1159/000542137↗
  4. Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from … Co-author DOI 10.1177/17588359251320768↗
  5. Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of dat… Co-author DOI 10.1177/17588359251393156↗
  6. Impact of biliary drainage for unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: retrospective results f… Co-author DOI 10.1186/s12885-025-14992-2↗
  7. Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pa… Co-author DOI 10.3389/fonc.2025.1626689↗
  8. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreat… Co-author DOI 10.1038/s41598-024-63172-y↗
  9. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/… Co-author DOI 10.1038/s41598-024-65689-8↗
  10. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retorospective ovservat… Co-author DOI 10.21203/rs.3.rs-3985196/v1↗
  11. Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-023-46924-0↗
  12. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retrospective observati… Co-author DOI 10.21203/rs.3.rs-3677172/v1↗
  13. A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. First author DOI 10.1097/md.0000000000026052↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junichi Nakazawa · 11 shared papers, 2023–2026 · strength 1.72
  2. Kenji Mitsugi · 11 shared papers, 2023–2026 · strength 1.72
  3. Shiho Arima · 11 shared papers, 2023–2026 · strength 1.72
  4. Futa Koga · 11 shared papers, 2023–2026 · strength 1.72
  5. Taro Shibuki · 11 shared papers, 2023–2026 · strength 1.72
  6. Mototsugu Shimokawa · 11 shared papers, 2023–2026 · strength 1.72
  7. Taiga Otsuka · 11 shared papers, 2023–2026 · strength 1.72
  8. Tsuyoshi Shirakawa · 11 shared papers, 2023–2026 · strength 1.72
  9. Azusa Komori · 11 shared papers, 2023–2026 · strength 1.72
  10. Hiroki Taguchi · 11 shared papers, 2023–2026 · strength 1.72
  11. Kazuo Nishikawa · 10 shared papers, 2023–2026 · strength 1.58
  12. Shuji Arita · 10 shared papers, 2023–2026 · strength 1.58
  13. Yasunori Kawaguchi · 10 shared papers, 2023–2026 · strength 1.58
  14. Yoshinobu Okabe · 6 shared papers, 2021–2024 · strength 0.79
  15. Masaru Fukahori · 5 shared papers, 2021–2025 · strength 0.73
  16. Akio Ido · 4 shared papers, 2023–2026 · strength 0.60
  17. Norio Ureshino · 3 shared papers, 2023–2025 · strength 0.44
  18. Yasushi Ide · 3 shared papers, 2023–2025 · strength 0.44
  19. Tomoko Kodama · 3 shared papers, 2023–2024 · strength 0.40
  20. Tomonori Araki · 2 shared papers, 2025 · strength 0.33
  21. Tomoyuki Ushijima · 2 shared papers, 2021–2023 · strength 0.26
  22. Atsuko Kakihara · 1 shared paper, 2026 · strength 0.20
  23. Akiko Todaka · 1 shared paper, 2025 · strength 0.17
  24. Tomomi Koike · 1 shared paper, 2025 · strength 0.17
  25. Yoshiki Naito · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.